5 recruiting, 3 not yet recruiting, 3 unknown, 1 active not recruiting. 13 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Recruiting 5, Not yet recruiting 3, Unknown 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow Thymic epithelial tumor: new trials by email Literature Review of Thymic epithelial tumor trials Research Report on Thymic epithelial tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hypofractionated Radiotherapy After Complete Resection for Stage II/III Thymic Epithelial Tumors Postoperative hypo-fractionated radiotherapy - Thymic Epithelial Tumor | Phase 2 | Recruiting | Tianjin Medical University Cancer Institute and Hospital | 49 | 2026-07-14 | 2026-07-10 |
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Cyclophosphamide, Fludarabine, EB-CAR30-NK - B2 Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-05-20 |
| 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors Cyclophosphamide, Doxorubicin, and Cisplatin (CAP), nab-Paclitaxel and Carboplatin - Thymoma and Thymic Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 116 | 2026-03-01 | 2026-03-11 |
| Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor Carbon ion radiotherapy, combined with platinum-based regimen - Thymic Epithelial Tumor, Radiotherapy Side Effect | Phase 2 | Recruiting | Jian Chen | 48 | 2025-07-01 | 2025-06-13 |
| RATT Vs. VATT for Early-stage TETs RATT, VATT - Thymic Epithelial Tumor | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 100 | 2024-11-01 | 2024-10-30 |
| The Clinical Study of Post-operative Proton Radiotherapy for Thymus Tumor Proton radiotherapy, combined platinum based chemotherapy - Thymus Epithelial Tumor, Proton Radiotherapy | Phase 2 | Recruiting | Jian Chen | 55 | 2024-05-06 | 2025-06-13 |
| Rivoceranib in Patients With Metastatic Thymic Epithelial Tumor Rivoceranib - Thymic Epithelial Tumor | Phase 2 | Not yet recruiting | Samsung Medical Center | 40 | 2024-05-01 | 2024-04-09 |
| PT-112 in Subjects With Thymoma and Thymic Carcinoma PT-112 - Thymic Epithelial Tumor, Recurrent Thymoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 53 | 2022-04-06 | 2026-10-16 |
| Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Toripalimab + Chemotherapy - Thymic Epithelial Tumor | Phase 2 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 15 | 2021-01-31 | 2023-04-04 |
| Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma M7824 - Thymic Epithelial Tumor, Recurrent Thymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 9 | 2020-12-26 | 2026-10-16 |
| Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors rhGM-CSF，Peginterferon alfa-b2，radiation - Thymic Epithelial Tumor | Phase 2 | Unknown | Shanghai Cancer Hospital, China | 65 | 2020-12-01 | 2020-08-18 |
| neoadjuvant_thymic Epithelial Tumor pembrolizumab, Radiation - Thymic Epithelial Tumor | Phase 2 | Unknown | Samsung Medical Center | 40 | 2019-04-29 | 2021-03-22 |
| Paclitaxel and Cisplatin for Thymic Neoplasm paclitaxel and cisplatin - Thymoma, Thymic Carcinoma | Phase 2 | Terminated | Korean Cancer Study Group | 39 | 2008-09-01 | 2013-04-12 |
Thymoma (5) · Radiation Injuries (2) · Thymus Neoplasms (2) · Mediastinal Neoplasms (1) · Peripheral Nervous System Diseases (1)
Hemic and Lymphatic Diseases (5) · Lymphatic Diseases (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Complex and Mixed (5) · Thoracic Neoplasms (5) · Thymus Neoplasms (3) · Wounds and Injuries (2) · Mediastinal Diseases (1) · Nervous System Diseases (1) · Neuromuscular Diseases (1) · Respiratory Tract Diseases (1) · Thoracic Diseases (1)
Cyclophosphamide (2) · 130-nm albumin-bound paclitaxel (1) · AP 1903 reagent (1) · Carboplatin (1) · Cisplatin (1) · Doxorubicin (1) · Drug Therapy (1) · Heavy Ion Radiotherapy (1) · Radiation (1) · TP protocol (1) · apatinib (1) · fludarabine (1) · pembrolizumab (1) · toripalimab (1)
Jian Chen (2) · National Cancer Institute (NCI) (2) · Samsung Medical Center (2) · Beijing Biotech (1) · Korean Cancer Study Group (1) · Shanghai Cancer Hospital, China (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Shanghai Zhongshan Hospital (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (7) · South Korea (3) · United States (2)
Arun Rajan, M.D. (2) · Jingfang Mao, PHD (2) · Dae Seog Heo, MD, PhD (1) · Fan Jiang, MD, PhD (1) · Wencheng Zhang, M.D. (1)